QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$73.04 USD
+1.17 (1.63%)
Updated Sep 29, 2023 04:00 PM ET
After-Market: $72.98 -0.06 (-0.08%) 7:10 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.04 USD
+1.17 (1.63%)
Updated Sep 29, 2023 04:00 PM ET
After-Market: $72.98 -0.06 (-0.08%) 7:10 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Zacks News
QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Are Investors Undervaluing Koninklijke Philips (PHG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down -14% in 4 Weeks, Here's Why You Should You Buy the Dip in QuidelOrtho (QDEL)
by Zacks Equity Research
QuidelOrtho (QDEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.
QuidelOrtho (QDEL) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
QuidelOrtho (QDEL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 4% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe QuidelOrtho (QDEL) Could Rally 29.87%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 29.9% upside potential for QuidelOrtho (QDEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Top Research Reports for Microsoft, Salesforce & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).
Are Investors Undervaluing QuidelOrtho (QDEL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.
QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.
QuidelOrtho (QDEL) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 28.57% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
QuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
by Zacks Equity Research
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China
by Zacks Equity Research
QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.
Are Investors Undervaluing PetIQ (PETQ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.